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Recombinant adeno-associated virus (rAAV) vectors have been shown to be useful for efficient gene delivery
to a variety of dividing and nondividing cells. Mechanisms responsible for the long-term, persistent expression
of the rAAV transgene are not well understood. In this study we investigated the kinetics of rAAV-mediated
human factor IX (hFIX) gene transfer into human primary myoblasts and myotubes. Transduction of both
myoblasts and myotubes occured with a similar and high efficiency. After 3 to 4 weeks of transduction, rAAV
with a cytomegalovirus (CMV) promoter showed 10- to 15-fold higher expression than that with a muscle-
specific creatine kinase enhancer linked to b-actin promoter. Factor IX expression from transduced myoblasts
as well as myotubes reached levels as high as approximately 2 mg of hFIX/106 cells/day. Southern blot analyses
of high-molecular-weight (HMW) cellular genomic and Hirt DNAs isolated from rAAV/CMVhFIXm1-trans-
duced cells showed that the conversion of single-stranded vector genomes to double-stranded DNA forms, but
not the level of the integrated forms in HMW DNA, correlated with increasing expression of the transgene.
Together, these results indicate that rAAV can transduce both proliferating and terminally differentiated
muscle cells at about the same efficiency, that expression of transgenes increases linearly over their lifetime
with no initial lag phase, and that increasing expression correlates with the appearance of double-stranded
episomal rAAV genomes. Evidence showing that the rAAV virions can copackage hFIX, presumably nonspe-
cifically, was also obtained.
Adeno-associated virus type 2 (AAV-2) is a nonpathogenic
(10, 11), 4.7-kb single-stranded DNA virus that requires coin-
fection with helper adenovirus or herpes simplex virus for
efficient replication (5, 12, 30). The viral genome contains two
open reading frames that express four Rep and three Cap
proteins and is flanked by the 145-bp terminal repeats, which
are the only cis-acting elements that are essential for replica-
tion, packaging, or integration (reviewed in reference 47).
Thus, the entire AAV genome, except for these repeats, can be
replaced by a transgene to form a recombinant AAV (rAAV)
(43, 57). The natural tissue tropism of wild-type AAV is for
lung epithelial cells; however, the recombinant vector has been
used to also efficiently target skeletal muscle, liver, retina,
brain, and gut epithelium (15, 20, 23, 24, 32, 34, 35, 60, 71, 77).
This nearly ubiquitous tropism can be partly explained by the
fact that AAV-2 apparently uses widely expressed molecules as
coreceptors, including heparan sulfate proteoglycan (primary
attachment receptor), fibroblast growth factor receptor 1, and
aVb5-integrin (52, 62, 63; J. Qui, H. Mizukami, and K. E.
Brown, Letter, Nat. Med. 5:467–468, 1999).
Either strand of the virus can be packaged in virions as a
single-stranded DNA (47). In an infected cell, this single-
stranded virion DNA is converted to a double-stranded form
by poorly defined mechanisms. In the absence of helper virus
coinfection, wild-type AAV integrates as concatamer and pref-
erentially but not exclusively at the AAVS1 locus on human
chromosome 19 by a process that requires viral Rep protein(s)
(33, 36, 40, 58). Upon subsequent helper virus infection, the
wild-type AAV genome is rescued and the virus enters the lytic
cycle, forming progeny virions and thus completing the viral
infection cycle. On the other hand, the genome maturation
kinetics is not well understood for the rAAV vector genome.
rAAV, delivered in the absence of helper virus and Rep pro-
tein, persists as a single-stranded genome for a certain period
in transduced tissues. Using host cell enzymes, the single-
stranded rAAV genome is converted to double-stranded forms
that may persist as linear or circular episomes and may also
appear in the high-molecular-weight (HMW) DNA. Integra-
tion of rAAV occurs at a low frequency, as monomers or
low-copy-numbers concatamers, and with a loss of chromo-
some 19 specificity (13, 33, 43, 48, 51, 53, 55). Poor under-
standing of rAAV genome maturation has added to the con-
fusion regarding what form(s) of rAAV, integrated or
episomal, is truly responsible for long-term transgene expres-
sion and persistence, both of which are the hallmarks of rAAV-
mediated gene transfer in muscle, liver, and other target or-
gans.
Skeletal muscle has turned out to be a promising tissue for
rAAV-mediated systemic delivery of transgene products. Effi-
cient systemic delivery of transgene products in skeletal muscle
has been clearly demonstrated (6, 16, 18, 73). High rAAV
transducibility, easy accessibility, low turnover of cells, and
high vascularity are salient features that make skeletal muscle
a preferred rAAV delivery tissue. The ability of skeletal muscle
to exhibit persistent expression of the rAAV transgene has
been well described (15, 23, 34, 71). The lifelong transgene
expression obtained in mice after rAAV-mediated gene trans-
fer is in part due to the inability to elicit a cell-mediated
immune response (31). These features of rAAV in muscle have
led to preclinical testing with hemophilia B mouse and dog
models and now to initial translational clinical testing (for a
review, see reference 54). Hemophilia B is caused by deficiency
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of blood coagulation factor IX (FIX), a key protein that occu-
pies a pivotal position in the coagulation cascade (17, 37, 41).
A single intramuscular injection of rAAV containing the
human, mouse, or canine FIX (hFIX, mFIX, or cFIX) expres-
sion unit into immunocompetent normal or hemophiliac mice
or dogs can result in the production of biologically active FIX
(27, 28, 76). In mice intramuscularly injected with rAAV vector
containing the hFIX expression unit (rAAV/hFIX), the level of
hFIX increases gradually over 5 to 10 weeks after a 1- to
2-week initial lag phase. Using rAAV/b-galactosidase vector,
such gradual increase in expression of transgene has also been
correlated with a concomitant increase in the integrated form
of the rAAV vector (15). Similarly, the integrated form of
rAAV correlates with transgene expression in liver-directed
rAAV in mice (44). Other groups have suggested a role for
episomal rAAV forms in the long-term persistence and expres-
sion in muscle (19). To clarify these issues, we analyzed the
kinetics of rAAV transduction using a human skeletal muscle
cell assay system. Primary human skeletal muscle cells can be
maintained for almost a month in culture, much longer than
mouse primary muscle cells, allowing us to analyze the detailed
initial kinetics of rAAV transduction.
MATERIALS AND METHODS
rAAV vectors. Plasmid pTR/Me4bAhFIXm1 containing the 2.8-kb human FIX
minigene (hFIXm1) (38) under the transcriptional control of four tandem copies
of muscle creatine kinase enhancer (Me4) and b-actin promoter (bA) (69) was
constructed by inserting the Me4-bA-hFIXm1 cassette between the AAV ter-
minal repeats in pTR-UF2 (described in reference 77). The Me4-bA-hFIXm1
fragment (4.4-kb) was obtained from pBS/Me4bAhFIXm1 by KpnI-BamHI di-
gestion. This fragment was inserted at the KpnI-BamHI sites of pTR-UF2 con-
taining AAV terminal repeats and bovine growth hormone (bGH) poly(A)
signal, thus generating pTR/Me4bAhFIXm1 (Fig. 1). pTR/CMVhFIXm1 was
constructed by inserting hFIXm1 (2.8-kb) into pTR-UF2 at the BamHI site
between the human cytomegalovirus (CMV) immediate-early gene enhancer/
promoter and bGH poly(A) signal (Fig. 1). The rAAV genomes produced from
these vectors, rAAV/CMVhFIXm1 and rAAV/Me4bAhFIXm1, were 4.0 and 4.9
kb in size, respectively.
Helper-free rAAV vectors were prepared by the triple plasmid cotransfection
method as previously described (39, 72). Briefly, 293 cells in a 100-mm-diameter
culture dish were cotransfected with 5 mg of rAAV plasmid, 5 mg of AAV helper
plasmid (pACG2), and 15 mg of adenovirus helper plasmid (pXX6) (1:1:1 molar
ratio). At 48 h posttransfection, the rAAV virions were released from the cells by
three freeze-thaw cycles and purified by (NH4)2SO4 fractionation and two se-
quential CsCl2 gradient centrifugations. The titer of rAAV was then determined
by the dot-blot hybridization assay. Following DNase digestion and proteinase K
treatment, 5-ml samples from each fraction were denatured and probed with a
radiolabelled BamHI fragment of hFIX cDNA. Serial dilutions of linearized
rAAV plasmid solution were used as DNA concentration standards to determine
the viral particle number titer (virus particles per milliliter). In our experience,
the number of infectious units is in the order of 500 to 1,000 times smaller than
the rAAV particle number. The rAAV preparation was then dialyzed against 10
mM Tris (pH 7.5)–140 mM NaCl–1 mM MgCl2–3% glycerol with three or four
changes of dialysis solution over 4 to 12 h. Virus aliquots were stored at 270°C
until use. No visible cytopathic effect was seen on myoblast cultures after infec-
tion with these rAAV preparations. Viral titers obtained were between 4.5 3
1011 and 2 3 1012 particles per ml for the several preparations used in this paper.
Isolation and maintenance of human myoblasts. Primary human myoblasts
were isolated from biopsy samples of healthy abdominal muscle tissue (rectus
abdominus) which were obtained from patients undergoing surgery (at sites
unrelated to abdominal muscle) at the Department of Surgery. Written consent
was obtained in accordance with institutional guidelines. Muscle tissue biopsy
specimens freshly obtained from 44- or 2-year-old individuals were immediately
placed in ice-cold human myoblast growth medium (HMB-GM) (see below) and
left overnight at 4°C. Myoblasts were isolated by using anti-CD56 antibody linked
to magnetic beads (B.-G. Chen and K. Kurachi, unpublished data) or by a
cloning method as previously described (74). The primary myoblasts obtained
were more than 99% free of fibroblasts, as judged by desmin immunofluores-
cence staining (data not shown), and were capable of complete differentiation
into myotubes. The primary myoblasts can be maintained in culture for at least
25 to 30 doublings (about 8 to 10 passages) (data not shown). The cells used in
this report were between passages 3 and 5. Myoblasts were routinely maintained
on 0.25% gelatin (Sigma, St. Louis, Mo.)-coated tissue culture dishes. The tissue
culture dishes were coated with gelatin by pipetting 0.25% (wt/vol) solution of
gelatin made in water, swirling the dishes to wet the surface, and removing the
solution before plating the cells. The growth-factor rich media, HMB-GM, used
for myoblasts in this paper were (i) Ham’s F10 medium (Sigma) supplemented
with 20% heat-inactivated fetal bovine serum (FBS; Gibco-BRL, Gaithersburg,
Md.), 5 ng of bovine fibroblast growth factor basic (R & D Systems, Minneapolis,
Minn.) per ml, and penicillin-streptomycin (pen-strep; Gibco-BRL); and (ii)
skeletal muscle growth medium (SKGM; Clonetics/Whittakar, San Diego, Calif.)
supplemented with 20% Dulbecco’s modified Eagle’s medium (DMEM; Gibco-
BRL), 5% FBS, and pen-strep. The differentiation medium used was DMEM
supplemented with 2.5% FBS and pen-strep.
Recombinant AAV transduction. For rAAV transduction, 3 3 105 human
myoblasts were routinely plated on 60-mm-diameter gelatin-coated culture
dishes and grown for 3 days to 90% confluency (;106 cells). The myoblasts were
then differentiated by being grown for 3 days in DMEM containing 2.5% FBS.
The medium was replaced every day. Fully differentiated myotubes or 90%
confluency myoblasts were infected with rAAV at a multiplicity of infection
(MOI) of 1 3 104, 1 3 105, or 5 3 105 particles/cell (ca. 1 3 1010, 1 3 1011, or
5 3 1011 particles/dish) for 2 h at 37°C with continuous rocking in 0.5 ml made
up with Opti-MEM-I medium (Gibco-BRL). The volume was then adjusted to 2
ml with medium containing BaSO4-treated FBS (75) and supplemented with 10
mg of vitamin K1 per ml (AquaMEPHYTON; Merck, West Point, Pa.). The
medium was collected daily, and fresh medium was added. In some experiments,
the infections were done in six-well plates. The medium collected was centri-
fuged for 30 s in a microcentrifuge to remove cell debris and stored at 270°C
until use. Levels of hFIX produced in the medium were estimated by enzyme-
linked immunosorbent assay (ELISA), using pooled normal human plasma
(George King Bio-Medical Inc., St. Overland Park, Kans.) as the standard, as
previously described (38). All samples were assayed in duplicate, and the sensi-
tivity of this ELISA was of the subnanogram order.
Isolation and analysis of HMW and Hirt DNAs. HMW (cellular genomic and
possibly some very large concatameric forms of rAAV) DNA was isolated from
infected cells at various times postinfection (p.i.). Cells were gently rinsed with
ice-cold phosphate-buffered saline and were harvested by scraping into 2 ml of
ice-cold phosphate-buffered saline. Cells from three 60-mm-diameter dishes
were pooled for each time point, and the genomic DNA fraction was obtained by
proteinase digestion of cells as described previously (45, 56). Stringy DNA
(HMW DNA), precipitated upon addition of 70% ethanol (final volume) to cell
lysates, was spooled out using a plastic pipette tip, transferred to a tube contain-
ing 70% ethanol, and pelleted by brief centrifugation at room temperature. The
DNA pellet was air dried and allowed to resuspend overnight in 20 to 100 ml of
TE (10 mM Tris-HCl [pH 8.0], 1 mM EDTA) at 4°C. After removal of HMW
DNA, the remaining original 70% ethanol solution was centrifuged at room
temperature for 15 min in a microcentrifuge to obtain Hirt DNA (unintegrated
low-molecular-weight DNA). The Hirt DNA pellet was washed with 70% etha-
nol and resuspended in 25 ml of TE containing RNase A (at 0.1 mg/ml [final
concentration]). This spooling method, which is routinely used for obtaining
high-quality genomic DNA from culture cells and various tissues, was used rather
than conventional Hirt precipitation (29) because this enabled us to prepare both
high-quality HMW and Hirt DNA preparations from the same cells. Southern
blot analysis of restricted genomic DNA (4 to 10 mg) was carried out on a 0.75%
agarose gel using 32P-radiolabelled probes (56). Specifically hybridized bands
FIG. 1. Structure of rAAV/Me4bAhFIXm1 and rAAV/CMVhFIXm1 con-
structs. rAAV/Me4bAhFIXm1 contains the hFIX minigene under the transcrip-
tional control of four tandem copies of the minimal MCK enhancer (Me4; total
size 1.2 kb) and 280-bp b-actin promoter. rAAV/CMVhFIXm1 contains the
620-bp CMV immediate-early gene enhancer-promoter, hFIX minigene, and
bGH poly(A) signal, flanked by AAV inverted terminal repeats. The CMV
promoter probe (0.62-kb EcoRI-BamHI fragment) used for Southern analysis is
shown by a dark line. The internal EcoRI fragment detected by the CMV
promoter probe is 1.9 kb (arrow a in Fig. 4 and 5). The line at the bottom
represents a 5-kb scale, with each mark representing 1 kb.
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were quantitated on a PhosphorImager (STORM system; Molecular Dynamics,
Sunnyvale, Calif.).
Transfection of human myoblasts. Primary myoblasts were transfected using
FuGENE 6 (Roche, Indianapolis, Ind.) as recommended by the manufacturer,
with modifications. Briefly, 2 3 105 myoblasts were plated per well of a six-well
plate coated with 0.25% gelatin and incubated overnight at 37°C. After 1 day,
cells at 70 to 80% confluency were transfected by centrifugation (30 min at
1,180 2 g and 32°C) after addition of a mixture of 3 mg of plasmid DNA
(precondensed by incubating with 3 mg of histone H1 protein [Roche] for 5 min
at room temperature) and 9 ml of FuGENE 6 on cells in a final volume of 1 ml
of medium. Centrifugation was performed using microtiter plate carrier. After
4 h, the transfection medium was replaced with 1 ml of growth medium (SKGM)
supplemented with BaSO4-treated FBS and 10 mg of vitamin K1 per ml. The
medium was collected every 24 h, and the hFIX produced was assayed by ELISA.
Expression obtained in the 24- to 48-h posttransfection period in repeated
experiments was reported.
Western blot analysis of rAAV/CMVhFIXm1 virions. rAAV preparations were
diluted to 1011 particles/ml in 50 mM Tris (pH 6.7). Sodium dodecyl sulfate
(SDS)-polyacrylamide gel-loading buffer (53) was added to the samples and
boiled for 5 min, and 2 or 4 ml was resolved on an SDS–10% polyacrylamide gel
and electroblotted onto polyvinylidene difluoride membranes as previously de-
scribed (42). The hFIX proteins on blots were visualized by sequential treatment
with goat anti-hFIX polyclonal antibody (obtained from Enzyme Research Lab-
oratories Inc., South Bend, Ind.) (used at 1:1,000 dilution in Tris-buffered saline
[TBS] [pH 7.5]), horseradish peroxidase-conjugated swine antigoat immunoglob-
ulin G (Roche) (1:5,000 dilution in TBS) and chemiluminescent reagents (ECL-
PLUS [Amersham]). The titers of rAAV/CMV-b-gal and wild-type AAV-2 used
as controls in these experiments were 5.5 3 1011 and 1.3 3 1011 particles/ml,
respectively. These vectors were produced from rAAV plasmids, pAB-11 and
pSub201, respectively, using the helper-free system as described above.
RESULTS AND DISCUSSION
Transduction of human myotubes with rAAV/CMVhFIXm1
results in much higher expression of transgene than does that
of rAAV/Me4bAhFIXm1. Previously we showed that Me4bA
muscle-specific promoter can drive high hFIX expression in
primary mouse myoblasts (69). To evaluate the expression of
hFIX transgene from the Me4bA promoter in rAAV-mediated
gene transfer, we constructed rAAV/Me4bAhFIXm1 vector
and compared it with the constitutive vector rAAV/CMVh-
FIXm1 (Fig. 1). Figure 2 shows the kinetics of hFIX produc-
tion from human myotubes after transduction with rAAV/
Me4bAhFIXm1 or rAAV/CMVhFIXm1. It is important to
note that longitudinal and detailed analysis of kinetics of
rAAV transduction and transgene expression was possible only
by using human muscle cells, which could be maintained viable
in culture for as long as 1 month. Mouse myotubes, on the
other hand, could not be maintained for more than 7 to 9 days
in culture (data not shown).
The human muscle cells were infected at a MOI of 104 rAAV
particles per cell and maintained in differentiation medium,
and the hFIX secreted was assayed by ELISA (Fig. 2A to
D). Myotubes directly transduced with rAAV/Me4bAhFIXm1
secreted ;14 ng of hFIX/106 cells/day, while myotubes trans-
duced with rAAV/CMVhFIXm1 produced almost 15-fold more
hFIX than did those transduced with rAAV/Me4bAhFIXm1,
almost 200 ng of hFIX/106 cells/day toward the end of the 4
weeks of the experimental period (Fig. 2A and C). In these
experiments, the cell numbers refer to myoblasts prior to dif-
ferentiation. Similar results were also obtained from myotubes
derived from myoblasts transduced prior to differentiation
(Fig. 2B and D). In the latter case, rAAV/Me4bAhFIXm1- or
rAAV/CMVhFIXm1-transduced cells secreted ;30 or ;300
ng of hFIX/106 cells/day, respectively, toward the end of ex-
perimental period. Production of hFIX from human myoblasts
transfected with rAAV vectors also showed a relative differ-
ence in hFIX expression levels; i.e., pTR/CMVhFIXm1-trans-
fected myoblasts produced fourfold more hFIX (15 6 5 ng/ml;
n 5 4) than did the pTR/Me4bAhFIXm1-transfected myo-
blasts (4 6 1 ng/ml; n 5 4). These experiments suggested that
the CMV promoter is substantially stronger than the Me4bA
transcriptional unit in human muscle cells. This is consistent
with observations made by others (1, 27, 28). The overall
hFIX production level from rAAV/Me4bAhFIXm1-trans-
duced human muscle cells was much lower than that from
pdLMe4bAhFIXm1-transfected mouse myoblasts (;750 ng of
hFIX/106 cells/day) (68). This difference may be due in part to
the source of enhancer-promoter used in Me4bA (the en-
hancer and promoter were of mouse and chicken origin, re-
spectively) (69). Therefore, we used rAAV/CMVhFIXm1 for
the following studies of the mechanisms responsible for rAAV
transduction of human skeletal muscle cells and the transgene
expression kinetics involved.
rAAV transduction of human myotubes and myoblasts re-
sults in similar and high hFIX production. Human skeletal
myotubes were transduced with rAAV/CMVhFIXm1 at a
MOI of 1 3 104, 1 3 105, or 5 3 105 and maintained in
differentiation medium (supplemented with 2.5% FBS) or in
rich medium (F10- or SKGM-based medium) (Fig. 2C to N).
Both F10- and SKGM-based media are routinely used as mus-
cle cell growth media. We tested both to see if these different
media have an effect on transgene expression. In addition, we
chose to maintain cells throughout in differentiation medium
because cells survive longer under these culture conditions,
allowing us to extend the duration of transgene expression. As
shown in Table 1 and Fig. 2C to N, a viral dose-response
relationship was obtained from transduced myotubes main-
tained in the F10-based medium. These cells showed maximal
hFIX production of ;600, ;800, or ;1,700 ng of hFIX/106
cells/day when transduced at a MOI of 1 3 104, 1 3 105, or 5 3
105, respectively (Fig. 2E, I, and M; Table 1). Myotubes in
differentiation medium produced lower levels of hFIX (;200
ng of hFIX/106 cells/day) (Fig. 2C and G). Similar to the results
with myotubes maintained in F10-based medium, the myo-
tubes in SKGM-based medium also produced high levels of
hFIX (Fig. 2K; Table 1). A similar dose-response relationship
was also obtained from myotubes derived from myoblasts,
which were transduced at 90% confluency prior to differenti-
ation (Fig. 2D, F, H, J, L, and N; and Table 1). However,
unlike direct transduction of myotubes, the expression of hFIX
did not necessarily increase linearly. This may be in part due to
the rAAV transduction process and subtle unknown effects of
induction of differentiation, although further studies are re-
quired to find the reason. The overall maximal hFIX expres-
sion in these experiments was 1,500 to 1,900 ng of hFIX/106
cells/day (Table 1). This supports the high capability of skeletal
muscle to express hFIX transgene, agreeing with previous ob-
servations in mouse muscle cells (68, 73).
Expression of hFIX from rAAV-transduced human skeletal
muscle cells occurs with no lag phase. As shown in Fig. 2, the
rAAV/CMVhFIXm1-transduced human myotubes showed no
appreciable lag period but showed a linear increase in hFIX
production (Fig. 2C, E, G, I, K, and M). In both mice and dogs
intramuscularly injected with rAAV/FIX, a lag phase of about
2 weeks followed by a slow rise over 5 to 8 weeks before
reaching stable constant levels is observed (27, 28). A similar
lag phase was also reported in b-galactosidase production in
mice intramuscularly injected with rAAV/b-gal (15). However,
in some experiments, wherein rAAV/erythropoitin was intra-
muscularly delivered to mice, no such lag phase was observed
and transgene expression was observed from as early as 4 days
p.i. (61, 67). One possible explanation for the observed lag in
detectable hFIX production in mice is a need to saturate hFIX
binding sites on endothelial cells and vascular tissue prior to
the appearance of detectable hFIX in the circulation (14, 27)
whereas the in vitro culture assay system is not affected by such
hFIX binding. Our observations with human muscle cells
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strongly support the notion that there is no appreciable initial
lag phase in hFIX production and are consistent with the
conceivable mechanism of slow but steady conversion of single-
to double-stranded rAAV genome.
rAAV virions can copackage hFIX protein. In some experi-
ments, as shown in Fig. 2, rAAV/CMVhFIXm1-transduced
muscle cells exhibited a high and transient hFIX production
during the first 2 days of transduction. Some previous reports
suggested that the CMV promoter has a differential activity in
different tissues and at various stages of organogenesis and
differentiation (7, 8, 59). The initial spike in hFIX levels is
probably not due to myoblast differentiation-specific effects,
FIG. 2. Production of hFIX from human muscle cells transduced with rAAV/Me4bAhFIXm1 or rAAV/CMVhFIXm1 vector. (A, C, E, G, I, K, and M) hFIX
production after direct transduction of myotubes (solid triangles); (B, D, F, H, J, L, and N) hFIX production from myotubes generated from transduced myoblasts (open
squares). Cells were transduced with rAAV/Me4bAhFIXm1 at a MOI of 1 3 104 (A and B) or rAAV/CMVhFIXm1 at a MOI of 1 3 104 (C to F), 1 3 105 (G to L),
and 5 3 105 (M and N). Cells were maintained in differentiation medium (A to D, G and H), F10-based medium (E, F, I, J, M, and N), or SKGM-based medium (K
and L). hFIX secreted per day was assayed by ELISA and is shown as mean and standard error of the mean (n 5 2 for panels A, B, E, and F; n 5 3 for panels C, D,
K, L, M, and N). For panels G, H, I, and J, the experiment was started with nine 60-mm dishes, and three dishes were used at each time point as described in the text.
For panels F, J, L, and N, myoblasts were differentiated by being transferred to differentiation medium for 3 days p.i., and then maintaining the cells in F10- or
SKGM-based rich medium as described in the text. No high or transient expression of hFIX was seen in panels K and L, presumably because a different rAAV batch
was used for them, which is different from those used for other experiments.
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because this transient expression was also observed in trans-
duction of fully differentiated myotubes (Fig. 2C, E, I, and M).
Since rAAV vectors can package either plus or minus strands
(9), the single-stranded DNA of both polarities must be
present in infected cells. Therefore, it is possible that some of
these strands anneal and form transcriptionally active double-
stranded forms. This scenario, however, provides only a partial
explanation because of the transient nature of hFIX expres-
sion. The notion of carryover of the rAAV plasmid vector used
for transfection of the 293 packaging cells to target cell trans-
duction medium is inconceivable, because of the several spe-
cific steps involved in rAAV purification.
FIG. 2—Continued.
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rAAV may nonspecifically trap transgene products, as pre-
viously suggested (4, 65). As shown in Fig. 2, the purified
rAAV virions were not removed after 2 h of infection and the
medium was made up to a total of 2 ml. Therefore, 1 day p.i.,
the medium still contained the rAAV virions that failed to
infect. Using a quantitative dot blot assay and a CMV pro-
moter probe, we showed that a substantial number of particles
failed to infect cells and remained in the medium after 1 day
(Table 2). These virions, if containing hFIX, might have con-
tributed to the hFIX levels measured by ELISA. We directly
tested rAAV/CMVhFIXm1 virions in an hFIX-specific ELISA.
Dilutions of rAAV/CMVhFIXm1 virions at 1011, 1010, or 109
particles/ml gave an average of 2,282, 272, or 8 ng of hFIX/ml,
respectively. Results of Western blot analysis of rAAV/CM
VhFIXm1 virion proteins is shown in Fig. 3. Wild-type AAV-2
or rAAV/CMV-b-gal virions prepared by the same helper-free
system as for rAAV/CMVhFIXm1 were used as controls along
with the purified hFIX protein. rAAV/CMVhFIXm1 virion
protein-containing lanes showed the anti-FIX reactive band of
56 kDa (lanes 2 and 7) at the same position as the plasma-
derived hFIX controls (lanes 1 and 6). Protein preparations
from rAAV/CMV-b-gal or wild-type AAV-2 virions or dilution
buffer alone did not show any corresponding bands (lanes 3 to
5 and 8 to 10). These results strongly supported the notion that
rAAV virions copackaged hFIX, and thus the transient hFIX
expression at 1 day p.i. in Fig. 2 can be almost fully accounted
for by hFIX protein contained in the rAAV virions and is not
due to transgene expression from infected cells. We previously
observed a transient partial correction of whole-blood clotting
time in dogs after 1 day of intramuscular injection of rAAV/
CMVhFIXm1 (46). This whole-blood clotting time correction
could not be expected on the basis of hFIX transgene expres-
sion. We propose that such partial WBCT correction may be
due to the delivery of hFIX protein copackaged in the rAAV
virions.
Integration of the rAAV transgene in cellular genomes does
not correlate with transgene expression. One of the major
unresolved issues regarding the rAAV transduction mecha-
nism is whether rAAV genome integration into the host cell
genome is needed for transgene expression. The human mus-
cle cell model described above provides a powerful system to
study the mechanisms governing rAAV transduction, because
the cell number (nucleus number) is effectively maintained
unchanged upon differentiation and thus any alterations ob-
served in the rAAV genome in these cells can be directly
correlated to the changes in transgene expression. Further-
more, it permits us to analyze actively proliferating cells and
terminally differentiated cells derived from them.
We isolated cellular genomic (HMW) DNA from rAAV/
CMVhFIXm1-transduced myotubes that were infected at a
MOI of 105 and maintained in F10-based rich medium (Fig.
2I). Presumably, this fraction may also contain some very large
concatameric forms of the rAAV vector. The HMW DNA was
subjected to Southern blot analysis using a CMV promoter-
specific probe (Fig. 1). As expected, this probe showed strict
transgene specificity, and no hybridization was seen with the
DNA isolated from uninfected myotubes (Fig. 4, lane 5). To
compare the amounts of rAAV genomes in HMW DNA frac-
tions at various times after transduction, the HMW DNA were
isolated from myotubes at 4, 10, and 19 days p.i. and digested
with EcoRI, which cleaves at the 59 end of the promoter and
within the hFIX intron to release a 1.9-kb band (Fig. 1 and 4).
As shown in Fig. 4 (lane 6), transgenes were clearly present in
HMW DNA on day 4 p.i., the earliest time point analyzed in
this study. The amount of transgene released from HMW
DNA on day 10 p.i. was not significantly different from that
obtained from the HMW DNA on day 19 p.i. (lanes 7 and 8).
To rule out a culture medium-specific effect, HMW DNA from
transduced myotubes, which were maintained in differentiation
medium, was also analyzed (Fig. 2G). As expected, the undi-
gested HMW DNA from transduced myotubes hybridized with
the CMV promoter probe showed the presence of transgene in
DNA larger than 12 kb (Fig. 5, lanes 10 to 12). Similar to the
above results, the amount of transgenes released from HMW
DNA on day 17 p.i. was not significantly different from the
amount released on day 28 p.i. in the transduced myotubes
(lanes 8 and 9).
HMW DNA isolated from cells transduced prior to differ-
entiation was also analyzed (Fig. 2H and J). HMW DNA
isolated from cells which were transduced prior to differenti-
TABLE 1. Average maximal expression of hFIX from human myotubes
MOI
Infection of myotubes (after differentiation)a: Infection of cells prior to differentiationa:
2.5% FBSb F10-based mediumb SKGM-based mediumb 2.5% FBS F10-based medium SKGM-based medium
1 3 104 200 600 NDc 300 600 ND
1 3 105 200 800 1900 310 1,000 1,500
5 3 105 ND 1,700 ND ND 1,300 ND
a Total expression of hFIX in nanograms per 106 cells per day.
b The cells were maintained in either of the three culture media as described in the text and Fig. 2.
c ND, not done.




Total no. of rAAV
particles added
No. of particles remaining
after 1 day
Total no. of
infective particlesb Effective MOI
c
104 Myotubes 4.4 3 105 4.4 3 109 0.8 3 109 3.6 3 109 8.1 3 103
104 Myoblasts 4.4 3 105 4.4 3 109 4 3 109 0.4 3 109 0.9 3 103
105 Myotubes 0.78 3 106 0.78 3 1011 0.9 3 1010 0.69 3 1011 8.8 3 104
105 Myoblasts 0.8 3 106 0.8 3 1011 0.3 3 1011 0.5 3 1011 6.2 3 104
a For a MOI of 104, the cells were infected in six-well plates; the other experiments were done in 6-cm dishes.
b Total infective particles is defined as a total rAAV added minus particles remaining after 1 day.
c Effective MOI is defined as total infective particles divided by total number of cells.
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ation and the resulting myotubes maintained in differentiation
medium showed transgene bands larger than 12 kb (Fig. 5,
lanes 4 to 6), similar to those obtained with HMW DNA
isolated from myotubes that were directly transduced (lanes 10
to 12). Importantly, the transgene amount on day 28 p.i. was
not significantly different from that on day 17 p.i. (lanes 2 and
3). On the other hand, the results obtained from the analysis of
HMW DNA isolated from cells that were transduced prior to
differentiation and maintained in F10-based rich medium
showed a somewhat nonlinear increase in hFIX expression
(Fig. 2J and Fig. 4, lanes 1 to 4). Nevertheless, the observations
from directly transduced myotubes and those from cells trans-
duced prior to differentiation and maintained in differentiation
medium suggested that the amount of vector genomes in
HMW DNA (presumably containing integrated rAAV ge-
nomes) does not correlate with the transgene expression level
in human muscle cells. Thus, the amount of HMW transgene,
often used as an important indicator of increasing and persis-
tent transgene expression, appears not to be a valid parameter
for increasing transgene expression in human muscle cells.
The HMW DNA fraction contains head-to-tail junctions in-
dicative of integrated and/or concatameric forms of rAAV. The
HMW DNA fraction may contain integrated as well as some
large concatameric forms of rAAV and/or small amounts of
trapped episomal forms. To show if a junction fragment could
be released from the HMW DNA, we digested HMW DNA
with an enzyme with a single recognition site, BstBI, and ana-
lyzed it by Southern blotting using the CMV promoter probe as
described above. The head-to-tail, head-to-head, or tail-to-tail
junctions should release a 4-, 6.3-, and 1.8-kb fragment, respec-
tively, and the end fragment should be detected as a 3.1-kb
band upon BstBI digestion (Fig. 1). As shown in Fig. 6, we
detected only the 4-kb fragment, which is indicative of a head-
to-tail junction (lanes 2 to 4). Such junctions are most probably
released from the integrated and/or cellular genome-associ-
ated large concatameric forms of rAAV. Although it may not
be significant, the possible presence of some circular episomes
trapped in the HMW DNA fraction cannot be ruled out at this
stage of study.
FIG. 3. Western blot analysis of rAAV virion-packaged proteins. rAAV
preparations diluted to 1011 particles/ml were resolved on an SDS–10% poly-
acrylamide gel and electroblotted onto polyvinylidene difluoride membranes.
The hFIX proteins on blots were visualized by the chemiluminescent detection
system. Lanes 2 to 4 and 7 to 9 were loaded with 4 or 2 ml of rAAV vectors,
respectively. Lanes 1 and 6 were loaded with 8 and 4 ng of purified plasma-
derived hFIX protein, respectively. Lanes 2 and 7 were loaded with rAAV/
CMVhFIXm1. Lanes 3 and 8 and lanes 4 and 9 were loaded with wild-type AAV
or rAAV/CMV-b-gal, respectively. Lanes 5 and 10 contain the dilution buffer
alone. The arrow indicates the position of the hFIX protein (56 kDa).
FIG. 4. Southern blot analysis of DNA isolated from rAAV/CMVhFIXm1-transduced cells. HMW and Hirt DNA were isolated from muscle cells transduced at
a MOI of 105 and maintained in F10-based medium (Fig. 2I and J). HMW or Hirt DNA was isolated 4 days p.i. (lanes 2, 6, 9, 12, 15, and 18), 10 days p.i. (lanes 3,
7, 10, 13, 16, and 19), or 19 days p.i. (lanes 4, 8, 11, 14, 17, and 20). Lanes: 2 to 4 and 9 to 11, HMW DNA from cells transduced at the myoblast stage; 6 to 8 and 12
to 14, HMW DNA from cells transduced at the myotube stage; 1 and 5 respective mock-infected control DNA isolated on day 4. HMW DNA (4 mg) was digested with
EcoRI and subjected to Southern blot analysis with the CMV promoter probe. Lanes 1 to 8 contain EcoRI-digested HMW DNAs, and lanes 9 to 14 contain undigested
HMW DNAs. Arrow a indicates the position of the 1.9-kb internal EcoRI fragment. The possible position for the .12-kb genomic DNA signal, more prominant in
Fig. 5, is shown by an asterisk. Lanes 15 to 17 contain Hirt DNA from cells transduced at the myoblast stage; lanes 18 to 20 contain Hirt DNA from cells transduced
at the myotube stage. Hirt DNA isolated from cells cultured in the rich medium tends to give less discernible bands, and undigested or digested genomic DNA show
bands of .4-kb (lanes 9 to 14) and ,1.9 kb (lanes 2 to 4 and 6 to 8), respectively. These bands, however, are not seen when genomic DNA prepared from
rAAV-transduced cells was grown in differentiation medium (see Fig. 5). At present, little is known about why genomic DNA from cells maintained in rich medium
with much active metabolism tends to have these bands.
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Upon reprobing of the blots (Fig. 5, HMW DNA) containing
EcoRI-digested fragments of transduced myoblasts or myo-
tubes with the rAAV ITR probe, a strong band between 1.5
and 2 kb was observed, which may arise from the free right end
of a linear DNA and/or head-to-tail junction of integrated,
concatameric, or episomal DNA (data not shown). Since free
linear forms are unlikely to be isolated in the HMW DNA
fraction, we conclude that both rAAV concatamers (at least
those of four units, since the hybridization with undigested
genomic DNA was seen in DNA larger than 12 kb [Fig. 4, lanes
9 to 14, and Fig. 5, lanes 4 to 6 and 10 to 12]) and circular
episomal forms may be present in the HMW fraction. How-
ever, as shown above, these forms do not increase concurrently
with transgene expression (Fig. 4 and 5). Thus, these results
argue against the proposed mechanism wherein ongoing am-
plification of the transgene sequences in integrated or episo-
mal concatamers is the primary mechanism leading to a steady
and long-term increase in expression.
Some groups have shown integration of rAAV by the isola-
tion of cellular-rAAV DNA junctions (references 48, 55, and
70 and references therein). These analyses have shown that
integration of rAAV is a low frequency event. Pulsed-field gel
electrophoresis and fluorescent in situ hybridization analyses
have also been performed to demonstrate chromosome-asso-
ciated rAAV (23, 44). Such analysis remains to be done on
HMW DNA in our human muscle cell assay system.
The conversion of single-stranded vector genomes to dou-
ble-stranded DNA forms in Hirt DNA, but not the stably
integrated form, correlates with the expression of transgene.
The slow but linear rise in hFIX level (in transduced myotubes
in this study) suggests that the pathway for conversion of the
single-stranded input viral genome to the transcriptionally ac-
tive form may be limited by several steps. The conversion of
single-stranded input vector to a double-stranded form is sug-
gested to be one of the primary rate-limiting steps (21, 22). To
determine if conversion of the single-stranded input viral ge-
nome to episomal forms is responsible for the slow linear rise
in transgene expression in myotubes, we analyzed the Hirt
DNA fraction. The HMW DNA was isolated by spooling, and
the remaining DNA was considered the Hirt fraction (see
Materials and Methods). The Hirt DNA was fractionated on
FIG. 5. Southern blot analysis of DNA isolated from rAAV/CMVhFIXm1-transduced cells. HMW and Hirt DNA was isolated from muscle cells transduced at a
MOI of 105 and maintained in differentiation medium (Fig. 2G and H). HMW or Hirt DNA was isolated 4 days p.i. (lanes 1, 4, 7, 10, 13, and 16), 17 days p.i. (lanes
2, 5, 8, 11, 14, and 17), or 28 days p.i. (lanes 3, 6, 9, 12, 15, and 18). Lanes: 1 to 6, HMW DNA from cells transduced at the myoblast stage; 7 to 12, HMW DNA from
cells transduced at the myotube stage. HMW DNA samples (10 mg) were digested with EcoRI and subjected to Southern blot analysis with the CMV promoter probe.
The undigested samples are shown in lanes 4 to 6 and 10 to 12. The Hirt DNA profile of rAAV/CMVhFIXm1-transduced cells is shown in lanes 13 to 18. Lanes: 13
to 15, Hirt DNA from cells transduced at the myoblast stage; 16 to 18, Hirt DNA from cells transduced at the myotube stage. Arrow a indicates the position of the
1.9-kb internal EcoRI fragment. Arrow b indicates the single-stranded rAAV genomes, and arrows c, d, and e indicate possible double-stranded forms of rAAV.
Determination of which band refers to monomer, dimer, or circular forms has yet to be done. The source of faint bands migrating at ,1.9 kb in some digested genomic
DNA samples (lanes 1 to 3 and 7 to 9) is not known. Since these ,1.9-kb and ;4-kb bands appear resistant, at least partially, to restriction digestion, they may be some
trapped single-stranded DNAs.
FIG. 6. Detection of head-to-tail junctions in HMW DNA. HMW DNA (4
mg) isolated from transduced myotubes (Fig. 2I) were digested with BstBI (lanes
1 to 4) or NotI (lanes 5 to 8) and analyzed by Southern blot analysis with the
CMV promoter-specific probe. HMW DNA was isolated 4 days p.i. (lanes 2 and
6), 10 days p.i. (lanes 3 and 7), or 19 days p.i. (lanes 4 and 8). Lanes 1 and 5
contain DNA from mock-infected controls. BstBI recognizes a single site in the
vector. The arrow indicates the expected head-to-tail junction. No NotI site exists
in the vector. NotI digestion did not release any distinct band and showed a
profile similar to that of undigested samples (Fig. 4, lanes 9 to 14).
3562 MALIK ET AL. J. VIROL.
an agarose gel and subjected to Southern blot analysis using a
CMV promoter-specific probe.
The Southern blot analysis of Hirt DNA isolated from cells
maintained in F10-based medium (Fig. 2I and J) is shown in
Fig. 4 (lanes 15 to 20). A smear of hybridization, which is
typically observed at the early stage in mice intramuscularly
injected with rAAV (15, 67), was seen at 4 days p.i. both in
transduced myotubes and when cells were transduced prior to
differentiation (Fig. 4, lanes 15 and 18). This smear, represent-
ing the single-stranded input rAAV vector (marked as ss
rAAV), resolved into more distinct bands on later days and the
double-stranded monomer Rf form appeared (lanes 16, 17, 19
and 20). These results obtained with human muscle cells are
generally consistent with previously published observations
with other cell types, which show slow conversion of single-
stranded input rAAV vector to the double-stranded monomer
Rf form (3, 21, 22).
A correlation between the slow conversion of single-
stranded input rAAV vector to double-stranded DNA forms
was clearly visible when the Hirt DNA isolated from cells
maintained in differentiation medium was analyzed (Fig. 2G
and H). As shown in Fig. 5, a smear of hybridization was seen
in transduced myotubes after 4 days, which resolved into dis-
tinct bands by day 17 (lanes 16 and 17). When the Hirt DNA
profiles in day 17 (lane 17) and day 28 (lane 18) samples were
compared, the smear representing single-stranded vector DNA
slowly disappeared and double-stranded DNA forms (linear
monomers, dimers, higher forms, and possibly circular episo-
mal forms) concomitantly increased in amount. Similar results
were obtained when Hirt DNA from cells that were transduced
prior to differentiation was analyzed (lanes 13 to 15). Phos-
phorImager analysis suggested a decrease of 20 to 30% in
single-stranded vector genomes and an increase in double-
stranded monomer and dimer forms of 100 to 200% from days
17 to 28 (Fig. 5, compared lane 14 to 15 or lane 17 to 18). In
transduced myotubes, the levels of hFIX increased from 128 to
168 ng of hFIX/106 cells/day, and in cells transduced prior to
differentiation, the increase in expression was from 242 to 316
ng of hFIX/106 cells/day for the period from days 17 to 28 p.i.
(Fig. 2G and H). In the former case, the levels did rise to ;200
ng of hFIX/106 cells/day between days 24 and 25, and the
apparent fall at the end is in part due to loss of cells by
detachment. Together, these results indicated that the increase
in the amount double-stranded forms of rAAV but not host
cell genome-integrated forms correlates with the increase in
expression of the hFIX transgene.
Possible significance of nonintegrated rAAV in transgene
expression in muscle. Several reports have concluded that the
integrated from of rAAV is responsible for the transgene ex-
pression and persistence in muscle (15, 23, 27, 71). In these
studies, the head-to-tail concatamers of rAAV often detected
by PCR or Southern blotting were taken as indicators of inte-
grated rAAV (15, 23, 27, 71). Miao et al. (44) reached a similar
conclusion in studies of transduced mouse liver. Up to 70-copy
concatamers of rAAV were found by pulsed-field gel electro-
phoresis and fluorescent in situ hybridization of metaphase or
interphase chromosome in transduced mouse liver, suggesting
the presence of an integrated form of rAAV (44). Although no
data exist so far, others have raised the possibility that rAAV
concatamers are not integrated but are in a tight association
with cellular DNA and/or nuclear matrix (2, 26, 67). An ex-
pected feature of rAAV genome maturation, which is generally
observed, is the gradual loss of single-stranded DNA in trans-
duced mouse muscle (15, 67). Clark et al. (15) observed in-
creasing transgene expression correlating with increasing levels
of transgenes in genomic DNA fraction (presumably integrat-
ed), whereas Vincent-Lacaze et al. (67) found a somewhat
inverse relationship. Such conflicting observations demon-
strate the difficulty in performing a reliable analysis of DNA
isolated from tissues of animals. The site of rAAV injection
and isolation of vector after the animal has aged for a period
will introduce numerous variables, including organ growth and
the possibility that cells processed for DNA do not truly rep-
resent the site of injection.
We developed a human muscle cell-based assay system to
study the kinetics and molecular events involved in rAAV
transduction and transgene expression. Our observations sup-
port the notion that the rAAV transgene level in the genomic
DNA (HMW) fraction does not correlate with transgene ex-
pression level during the period of linear increase of transgene
expression. At this stage, however, we cannot completely rule
out the possibility that HMW fraction transgenes are respon-
sible, at least in part, for long-term persistent hFIX expression
in animals (27, 28). We further showed that the recruitment of
single-stranded rAAV to double-stranded forms (linear or cir-
cular episomal) correlates with expression.
The importance of episomal forms is increasingly recognized
as the dominant factor in rAAV-mediated expression and per-
sistence. In one of the earliest studies, rAAV genomes were
present as approximately 8 kb (double-stranded dimer size) in
Hirt DNA and none were detected in the genomic DNA frac-
tion isolated 14 days p.i. from a rAAV/b-gal or rAAV/neo-
transduced IB3-1 cell line, a tetraploid human cystic fibrosis
bronchial epithelial cell line (25). Similar results were obtained
in vivo from rAAV-transduced primary bronchial epithelial
cells isolated from monkeys (2). These experiments did not
rule out the possibility that the 8-kb DNA represents only
double-stranded dimer forms and/or episomal forms (2, 25).
The episomal forms of rAAV may contain linear or circular
double-stranded monomers, dimers, or higher forms. Not sur-
prisingly, circular episomal forms have been selectively rescued
from transduced mouse muscle (19). Our experiments with the
human muscle cell assay system suggest that the unintegrated
low-molecular-weight episomal rAAV forms may be primarily
responsible for transgene expression and possibly play a critical
role in long-term persistence of expression. Wild-type AAV or
rAAV vectors require Rep68 or Rep78 protein for site-specific
integration (50, 64). The plasmids containing ITR elements
exhibit long-term persistence in transfected cells (19, 49, 66).
Thus, the rAAV episomal forms, unable to efficiently integrate
in the absence of Rep68 and Rep78, may stably persist in
transduced human myotubes and function as the predominant
source of transcriptionally active DNA. However, our results
do not rule out the possibility that some of these rAAV epi-
somes are further converted into higher concatmeric forms
and/or integrate into genomic DNA, which may also contribute
to the lifelong persistence of transgene expression observed in
mice. Various rAAV episomal forms in the Hirt DNA fraction
remain to be analyzed for a specific fraction(s) responsible for
hFIX expression. In summary, we have successfully developed
a human muscle cell assay system for further dissecting the
transduction mechanisms of rAAV.
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